DSpace DSpace UPC
 Català   Castellano   English  

E-prints UPC >
Altres >
Enviament des de DRAC >

Empreu aquest identificador per citar o enllaçar aquest ítem: http://hdl.handle.net/2117/17091

Arxiu Descripció MidaFormat
2012_PLoS1_Pardo.pdfArticle a la revista PLoS One304,88 kBAdobe PDFThumbnail
Veure/Obrir

Citació: Pardo-Lozano, R. [et al.]. Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy''): the influence of gender and genetics (CYP2D6, COMT, 5-HTT). "PLoS One", 24 Octubre 2012, vol. 7, núm. 10, p. 1-10.
Títol: Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy''): the influence of gender and genetics (CYP2D6, COMT, 5-HTT)
Autor: Pardo-Lozano, Ricardo; Farré, Magí; Yubero-Lahoz, Samanta; O’Mathúna, Brian; Torrens, M.; Mustata, Cristina; Pérez-Mañá, Clara; Langohr, Klaus Veure Producció científica UPC; Cuyàs, Elisabet; Carbó, Marcel·lí; de la Torre, Rafael
Data: 24-oct-2012
Tipus de document: Article
Resum: The synthetic psychostimulant MDMA (63,4-methylenedioxymethamphetamine, ecstasy) acts as an indirect serotonin, dopamine, and norepinephrine agonist and as a mechanism-based inhibitor of the cytochrome P-450 2D6 (CYP2D6). It has been suggested that women are more sensitive to MDMA effects than men but no clinical experimental studies have satisfactorily evaluated the factors contributing to such observations. There are no studies evaluating the influence of genetic polymorphism on the pharmacokinetics (CYP2D6; catechol-O-methyltransferase, COMT) and pharmacological effects of MDMA (serotonin transporter, 5-HTT; COMT). This clinical study was designed to evaluate the pharmacokinetics and physiological and subjective effects of MDMA considering gender and the genetic polymorphisms of CYP2D6, COMT, and 5-HTT. A total of 27 (12 women) healthy, recreational users of ecstasy were included (all extensive metabolizers for CYP2D6). A single oral weight-adjusted dose of MDMA was administered (1.4 mg/kg, range 75–100 mg) which was similar to recreational doses. None of the women were taking oral contraceptives and the experimental session was performed during the early follicular phase of their menstrual cycle. Principal findings show that subjects reached similar MDMA plasma concentrations, and experienced similar positive effects, irrespective of gender or CYP2D6 (not taking into consideration poor or ultra-rapid metabolizers) or COMT genotypes. However, HMMA plasma concentrations were linked to CYP2D6 genotype (higher with two functional alleles). Female subjects displayed more intense physiological (heart rate, and oral temperature) and negative effects (dizziness, sedation, depression, and psychotic symptoms). Genotypes of COMT val158met or 5-HTTLPR with high functionality (val/val or l/*) determined greater cardiovascular effects, and with low functionality (met/* or s/s) negative subjective effects (dizziness, anxiety, sedation). In conclusion, the contribution of MDMA pharmacokinetics following 1.4 mg/kg MDMA to the gender differences observed in drug effects appears to be negligible or even null. In contrast, 5-HTTLPR and COMT val158met genotypes play a major role.
ISSN: 1932-6203
URI: http://hdl.handle.net/2117/17091
DOI: 10.1371/journal.pone.0047599
Versió de l'editor: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0047599
Apareix a les col·leccions:Altres. Enviament des de DRAC
GREMA - Grup de Recerca en Estadística Matemàtica i les seves Aplicacions. Articles de revista
Departament d'Estadística i Investigació Operativa. Articles de revista
Comparteix:


Stats Mostra les estadístiques d'aquest ítem

SFX Query

Aquest ítem (excepte textos i imatges no creats per l'autor) està subjecte a una llicència de Creative Commons Llicència Creative Commons
Creative Commons

 

Valid XHTML 1.0! Programari DSpace Copyright © 2002-2004 MIT and Hewlett-Packard Comentaris
Universitat Politècnica de Catalunya. Servei de Biblioteques, Publicacions i Arxius